The Latin America, Middle East and Africa Gastric Cancer Market would witness market growth of 20.9% CAGR during the forecast period (2023-2029).
A promising potential in the market for treating gastric cancer is the development of combination treatments. Combined medicines can have several benefits, including increased efficacy and decreased toxicity compared to single-agent therapy. For patients with advanced gastric cancer, certain clinical trials have demonstrated that combining chemotherapy and immunotherapy can improve results.
It is also anticipated that other combination medicines, like targeted therapies and radiation therapy, may effectively treat gastric cancer. This strategy may assist in lessening adverse effects while improving treatment results. Due to the large unmet medical need for treating gastric cancer and the potential advantages of combination therapy, there is a considerable opportunity for businesses to create novel treatments in this field.
Cancer impacts over one million Latin Americans. The rising prevalence of cancer may be attributed to factors such as an aging demographic, the adoption of Westernized lifestyles, and urbanization. Los Angeles exhibits a high prevalence of gastric cancer compared to other nations. Gastric cancer is a significant health concern in Latin America, with several countries experiencing high mortality rates, including Chile, Costa Rica, and Colombia. The all-cause mortality rate is expected to increase in Latin America due to the developing and aging populations, resulting in a rise from fourteenth to eighth place shortly. The ASMR for males per 100,000 is higher in Honduras (22.3), Costa Rica (16.8), Peru (18.2), Chile (15.0), and Ecuador (20.7) compared to other regions of Latin America, such as Argentina.
The Brazil market dominated the LAMEA Gastric Cancer Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $121.6 million by 2029. The Argentina market is estimated to grow a CAGR of 21.6% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 20.6% during (2023 - 2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Gastric Cancer Market is Projected to reach USD 6.9 Billion by 2029, at a CAGR of 17.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
By Route of Administration
By Treatment Type
By Disease Type
By Distribution Channel
By Drug Class
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 